Medhanie Tesfay Gebrekidan1,2,3, Ramona Erber4, Arndt Hartmann4, Peter A Fasching4, Julius Emons5, Mathias W Beckmann5, Andreas Braeuer1,2,3. 1. 1 Lehrstuhl für Technische Thermodynamik, Friedrich-Alexander-Universität (FAU), Erlangen-Nürnberg, Germany. 2. 2 Erlangen Graduate School in Advanced Optical Technologies (SAOT), Friedrich-Alexander-Universität (FAU), Erlangen-Nürnberg, Germany. 3. 3 Institut für Thermische Verfahrenstechnik, Umwelt- und Naturstoffverfahrenstechnik, Technische Universität Bergakademie Freiberg (TUBAF), Freiberg, Germany. 4. 4 Pathologisches Institut, Friedrich-Alexander-Universität (FAU), Erlangen-Nürnberg, Germany. 5. 5 Frauenklinik, Friedrich-Alexander-Universität (FAU), Erlangen-Nürnberg, Germany.
Abstract
We used a shifted-excitation Raman difference spectroscopy method for the ex vivo classification of resected and formalin-fixed breast tissue samples as normal (healthy) tissue, fibroadenoma, or invasive carcinoma. We analyzed 8 tissue samples containing invasive carcinoma that were surrounded by normal tissue and 3 tissue samples with fibroadenoma only. We made various measurement sites on various tissue samples, in total 240 measurements for each type of tissue. Although the acquired raw spectra contain enough information to clearly differentiate between normal and tumor (fibroadenoma and invasive carcinoma) tissue, the differentiation between fibroadenoma and invasive carcinoma was possible only after the shifted-excitation Raman difference spectroscopy isolation of pure Raman spectra from the heavily fluorescence interfered raw spectra. We used 784 and 785 nm as excitation wavelengths for the shifted-excitation Raman difference spectroscopy method. The differences in the obtained pure Raman spectra are assigned to the different chemical compositions of normal breast tissue, fibroadenoma, and invasive breast carcinoma. Principal component analysis and linear discriminant analysis showed excellent classification results in the Raman shift range between 1000 and 1800 cm-1. Invasive breast carcinoma was identified with 99.15% sensitivity, and the absence of invasive carcinoma was identified with 90.40% specificity. Tumor tissue in tumor-containing tissue was identified with 100% sensitivity, and the absence of tumor in no-tumor containing tissue was identified with 100% specificity. As gold standard for the determination of the sensitivity and the specificity, we considered the conventional histopathological classification. In summary, shifted-excitation Raman difference spectroscopy could be potentially very useful to support histopathological diagnosis in breast pathology.
We used a shifted-excitation Raman difference spectroscopy method for the ex vivo classification of resected and formalin-fixed breast tissue samples as normal (healthy) tissue, fibroadenoma, or invasive carcinoma. We analyzed 8 tissue samples containing invasive carcinoma that were surrounded by normal tissue and 3 tissue samples with fibroadenoma only. We made various measurement sites on various tissue samples, in total 240 measurements for each type of tissue. Although the acquired raw spectra contain enough information to clearly differentiate between normal and tumor (fibroadenoma and invasive carcinoma) tissue, the differentiation between fibroadenoma and invasive carcinoma was possible only after the shifted-excitation Raman difference spectroscopy isolation of pure Raman spectra from the heavily fluorescence interfered raw spectra. We used 784 and 785 nm as excitation wavelengths for the shifted-excitation Raman difference spectroscopy method. The differences in the obtained pure Raman spectra are assigned to the different chemical compositions of normal breast tissue, fibroadenoma, and invasive breast carcinoma. Principal component analysis and linear discriminant analysis showed excellent classification results in the Raman shift range between 1000 and 1800 cm-1. Invasive breast carcinoma was identified with 99.15% sensitivity, and the absence of invasive carcinoma was identified with 90.40% specificity. Tumor tissue in tumor-containing tissue was identified with 100% sensitivity, and the absence of tumor in no-tumor containing tissue was identified with 100% specificity. As gold standard for the determination of the sensitivity and the specificity, we considered the conventional histopathological classification. In summary, shifted-excitation Raman difference spectroscopy could be potentially very useful to support histopathological diagnosis in breast pathology.
Breast cancer is one of the most frequent cancers worldwide. Each year 1.38 million new
cases are detected while 458 000 people die from this cause.[1] Breast tumors can be detected and localized using different well-established
noninvasive methods such as ultrasound, mammography, computer tomography, magnetic resonance
imaging, and positron emission tomography.[1-3] Nevertheless, invasive biopsy and a subsequent histopathological analysis is required
for the classification of the tumor as benign or malign.[1] Furthermore, the boundaries between normal breast parenchyma and malignant tumors
from resected tissues need extensive histopathologic analysis from many locations in order
to define resection status, and thus, it is time consuming. Evidently, this shows the
importance of developing fast and objective methods for the diagnosis of breast tumors. The
formation of tumor significantly changes the structure and composition of tissue, such as
the content of carbohydrates, lipids, proteins, and nucleic acids.[4] These changes occur even before the clinical symptoms emerge.[4]Biological material such as proteins, carbohydrates, lipids, nucleic acids, and DNA feature
different molecular structures[5] with this different Raman spectra.[6-8] Thus, the composition of biological tissues can be identified based on their Raman spectrum.[9] When any physiological change or pathological process changes the biochemistry of the
tissue, this leads to a change in its Raman spectrum.[10] This provides the potential for classifying diseases, such as breast tumors, in the
early stage.Manoharan et al
[11] investigated breast tissues using near-infrared (NIR) Raman spectroscopy. They stated
that the Raman spectrum of normal tissue is governed by lipid bands, whereas the spectrum of
the malign tissue is governed by protein bands. While normal cells store their energy in the
form of lipids, pathological cells synthesize large amounts of protein for the modulation
and maintenance of cellular activities of their uncontrolled growth.[12] By assigning Raman signal peaks or bands to molecular vibrations, they confirmed the
histopathologically derived knowledge that the majority of the proteins in the tumor is
collagen.Li et al
[4] discovered that the raw Raman spectra of normal breast tissue feature clearly
detectable Raman signal peaks, while the spectra of tumors, irrespective of whether they are
malignant or benign, are dominated by a strong and broadband autofluorescence interference,
which makes the identification of Raman signal peaks challenging. The fluorescence increase
in the tumor tissue may be related to the generation of precursors of fluorescent compounds
during the depletion of lipids.[13]Haka et al
[14] demonstrated that Raman spectroscopy is a promising new tool for real-time diagnosis
of breast tissue abnormalities. By applying a diagnostic model based on fit coefficients for
collagen and fat, they differentiated between normal tissue and malign and benign
tumors.Various techniques based on Raman scattering such as conventional NIR Raman spectroscopy,[15-20] surface-enhanced Raman spectroscopy (SERS),[1,2,21,22] and resonance Raman spectroscopy[13,23,24] have been used to analyze breast tumors. They all have in common that they are
optimized to the enhancement of the desired Raman signals with respect to the undesired
autofluorescence interferences or to the suppression or attenuation of the undesired
autofluorescence interferences. Conventional Raman spectroscopy gives optimal performance
for the characterization of breast tissues at excitation wavelength in the NIR spectral region[25] because of the relatively low excitation of the autofluorescence background.
Nevertheless, the undesired fluorescence background still interferes with the desired Raman
signals, especially in the spectra acquired from tumor tissues. The purification of the
Raman spectra from the autofluorescence interfered spectra using mathematical baseline
correction methods[26-28] bears the risk of not only eliminating the interfering fluorescence but also
eliminating or influencing Raman signatures.Resonance Raman spectroscopy is a variant of conventional Raman spectroscopy that involves
the careful selection of the excitation laser energy to nearly coincide with an electronic
transition of the target molecule. As a consequence, the detection limits and measurement
times can be significantly decreased.[29] However, only the resonantly excited transitions can be probed, which makes
multispecies detection and tissue composition analysis challenging.Surface-enhanced Raman spectroscopy is another variant of Raman spectroscopy that features
especially a high sensitivity. Here, a material, usually metallic nanoparticles, that
supports the enhancement of the Raman signal coming from the molecules in the proximity of
its surface has to be added to the probed sample.[30,31] Applying SERS, Vargas-Obieta et al
[1] reported a strong Raman signal enhancement and the differentiation between patients
with breast cancer and healthy patients with high sensitivity and specificity. Biocompatible
and nontoxic nanoparticles have been developed, which allow SERS to become applicable in an
in vivo setting.[32,33] However, the signal enhancement depends on several factors including the properties
of the metal, the shape and size of the nanoparticle, and the excitation wavelength. Thus,
SERS requires an intensive sample preparation and a complex experimental setup.We here applied shifted-excitation Raman difference spectroscopy (SERDS) for the
purification of Raman signals from heavily fluorescence-interfered spectra of invasive
breast carcinoma (malignant breast tumors) and fibroadenoma (benign breast tumors). To the
best of our knowledge, this is the first report of using SERDS for breast tumor
identification. This technique has been established as a useful tool for applying Raman
spectroscopy to samples with strong fluorescence interference.[34-36] Shreve et al
[34] were the first to propose the SERDS technique for fluorescence rejection. It is based
on Kasha rule[37] that the fluorescence signal is nearly insensitive to small photon energy excitation
changes in contrast to the Raman spectrum, which shifts according to the excitation photon
energy change. Thus, subtracting 2 raw spectra, each one excited with a slightly different
photon energy, enables the elimination of the fluorescence background, while a Raman
difference spectrum remains. da Silva Martins et al
[38] described SERDS as a very systematic and reproducible method for the elimination of
undesired fluorescence interferences. The SERDS technique is very effective, as it does
neither require any kind of sample preparation nor a complex experimental setup and is
capable of eliminating both, fluorescence interferences and systematic noise from spectra.[39] The charm of the SERDS technique is that the fluorescence is eliminated mainly
because of physical approach. Thus, in contrast to purely mathematical-based baseline
correction approaches, it does not affect the Raman features of the spectrum.
Materials and Methods
Sample
Spectra were collected from resected formalin-fixed samples of invasive breast carcinoma,
fibroadenoma, and normal breast tissues. The formalin fixation does not interfere with the
tissue analysis using Raman spectroscopy,[40] as it will be demonstrated also in the results section of this article. A total of
11 breast tissue samples were obtained from female patients undergoing breast cancer
diagnosis at the Department of Gynaecology and Obstetrics at the Institute of Pathology,
University Hospital Erlangen.The 11 breast tumor samples included 3 fibroadenoma and 8 invasive breast carcinoma. The
study protocol was approved by the Ethics Committee of University Hospital Erlangen
(178_16 Bc). Figure 1 shows
resected formalin-fixed breast tissue samples of an invasive carcinoma surrounded by
healthy tissue at the top and a fibroadenoma tumor at the bottom.
Figure 1.
Illustration of breast tissue samples. Invasive carcinoma (top) including healthy
safety margin and fibroademona (bottom).
Illustration of breast tissue samples. Invasive carcinoma (top) including healthy
safety margin and fibroademona (bottom).
Experimental Setup
Figure 2 shows the setup of the
self-developed Raman sensor. A diode laser (Toptica DLpro, Munich, Germany) with a
variable laser wavelength tunable between 770 and 810 nm, and a linewidth of <500 kHz
was used as the excitation light source. The excitation beam is launched into a glass
fiber, which guides the laser radiation to a Raman probe. Inside the Raman probe, a short
pass filter (785 nm cutoff wavelength) suppresses wavelengths longer than 785 nm
originating from fiber–light interactions when the excitation light passes through the
glass fiber. The excitation laser beam is then reflected via a dichroic mirror, which is
highly reflective for the excitation wavelength but transparent for wavelengths longer
than 785 nm. It is then focused through a lens onto the sample with a focal spot diameter
of approximately 200 μm. A portion of the excited signals (these are mainly elastic light
scattering signals, fluorescence, and the desired Raman signals) is detected in
back-scattering direction through the same lens. The red-shifted fluorescence and Raman
signals pass the dichroic mirror toward another lens focusing them onto a detection glass
fiber bundle guiding the signals from the Raman probe to the spectrometer (Ventana from
Ocean Optics, Largo, Florida). The elastic light scattering signals are filtered out,
first, by the dichroic mirror reflecting them toward the excitation glass fiber and,
second, by a long pass filter mounted between the dichroic mirror and the signal focusing
lens. The Ventana spectrometer analyzes the spectra between 800 and 940 nm, which
corresponds to Raman shifts from 200 to 2000 cm−1. The spectral resolution is
specified at 810 nm to be 10 cm−1. At 810 nm, a wavenumber difference of 10
cm−1 corresponds to approximately 0.6 nm. Therefore, signals with a
wavelength difference of minimum 0.6 nm can be spectrally resolved as 2 different peaks.
With 1024 pixels along the spectral axis of the detector, one pixel corresponds to
approximately 0.137 nm (∼2.44 cm−1), which is below the spectral
resolution.
Figure 2.
Custom-built, compact, and portable Raman sensor consisting of a tunable diode laser,
a fiber-coupled spectrometer and Raman probe.
Custom-built, compact, and portable Raman sensor consisting of a tunable diode laser,
a fiber-coupled spectrometer and Raman probe.Three combined and electrically driven linear translation stages (NRT150 from Thorlabs,
Newton, New Jersey) were used to move the handheld Raman probe to selected points on the
sample in the xyz-space. The 3-dimensional (3D) coordinates of a selected measurement
point on the sample were provided by a 3D visualization system (Ensenso N10 stereo
camera). This combination of translation stages and 3D camera made the subsequent
detection of Raman spectra from many different measurement points on the tissue sample
efficient.
Measurement Procedure
From each of the 8 tissue samples containing an invasive carcinoma, 30 measurement points
were selected in the region of the invasive carcinoma, and another 30 measurement points
were selected in the healthy tissue safety margin surrounding the carcinoma. From each of
the 3 fibroadenoma samples, 80 measurement points were selected. A minimum distance of 1
mm was maintained between the selected measurement points on each tissue sample, which is
more than 4 times the focal spot size of the laser. Thus, in summary, Raman spectra of
invasive carcinoma were obtained from 240 measurement points (30 points × 8 patients),
Raman spectra of healthy tissue were also obtained from 240 measurement points (30 points
× 8 patients), and Raman spectra of fibroadenoma were obtained from 240 measurement points
(80 points × 3 patients). The visual selection of the measurement points was confirmed by
a responsible surgeon from the Institute of Pathology of the University Hospital of
Erlangen.At each of the selected measurement points, first 50 spectra were acquired using the
excitation wavelength 784 nm. The acquisition of 1 spectrum took 300 milliseconds, and the
acquisition of 50 spectra took consequently 15 seconds. Then, the excitation wavelength
was automatically shifted to 785 nm, and from the same measurement point another 50
spectra were recorded. For both excitation wavelengths, the mean spectra were computed.
Afterward the same procedure was repeated at the next measurement point to which the Raman
probe moved automatically. For the elimination of the interfering fluorescence background
from the acquired spectra according to the SERDS method, the computed mean spectra were
used.
Data Analysis
The extraction of pure Raman spectra from heavily fluorescence interfered spectra
according to the SERDS method is described by Gebrekidan et al
[41] in detail. It is described here briefly. We used simulated Gaussian peaks and a
simulated fluorescence background to illustrate the SERDS method diagrammatically in Figure 3. Through a slight shift in
the excitation wavelength, 2 different mean spectra are acquired. The 2 mean spectra, one
for each excitation wavelength (784 and 785 nm), are first z score
normalized to bring the similarity of the 2 fluorescence contributions closer to the Kasha
rule, which states that the fluorescence emission is unaltered for a small change in the
excitation photon energy, while the Raman spectrum shifts according to the excitation
photon energy change as mimed in Figure
3A. Then, 1 of the 2 z score normalized mean spectra is
subtracted from the other one, that is, signal “b” subtracted from signal “a” in Figure 3A. As the fluorescence
background is supposed to be not influenced by the excitation wavelength, the majority of
the fluorescence background is eliminated by this subtraction via a physical approach. On
the contrary, the spectral position of the Raman peaks is a function of the excitation
wavelength (excitation photon energy). Ideally, the subtraction would result in a pure
Raman-difference spectrum. However, due to photo bleaching, in practice, the resulting
difference spectrum, as shown in Figure
3B (blue line), still contains fluorescence residuals. The residual fluorescence
interference, which compared to the original fluorescence levels is orders of magnitude
less, is eliminated further following mathematical approaches. First, the center of the
difference spectrum is identified using an asymmetric least squares fit which is
illustrated in Figure 3B (red
line). It is then subtracted from the difference spectrum (signal “c” minus signal “d” in
Figure 3B) to give a
center-corrected difference spectrum shown in Figure 3B (black line). Figure 3C (blue line) shows a spectrum reconstructed
from the center-corrected difference spectrum using a mathematical recurrence relation.
The obtained reconstructed spectrum still contains a weak fluorescence background which is
eliminated further by applying a baseline correction based on piecewise asymmetric least
squares fitting that is illustrated in Figure 3C (red line). Finally, a pure Raman spectrum is obtained as shown in
Figure 3D. Automatic acquisition
of spectra from selected measurement points and subsequent extraction of pure Raman
spectra following the SERDS method were performed using an in-house developed software
application in LABVIEW 2014 graphical programming language.
Figure 3.
Illustration of efficient isolation of Raman spectrum from extreme fluorescence
interference.
Illustration of efficient isolation of Raman spectrum from extreme fluorescence
interference.In order to distinguish between healthy breast tissue, fibroadenoma, and invasive
carcinoma based on their purified Raman spectra, we implemented a multiclass linear
discriminant analysis (LDA)[42] using in-house written scripts in the MATLAB programming environment (MathWorks,
Inc., Natick, Massachusetts). In order to improve the performance of LDA, we performed a
dimensionality reduction in the Raman spectra based on principal component analysis (PCA).[43] The PCA transforms the original data set into a new data set with transformed
variables (principal components) that are linear combinations of the original variables.
The principal components are arranged such that the variability of the original data set
is contained in descending order in the first principal components.We performed the differentiation between the different types of breast tissues by
dividing the data set into training and test data sets in an iteration loop based on the
leave-one-out cross validation. In each cross-validation iteration, 10 of the 11 tissue
samples (training data set) were used to train the PCA/LDA classifier. For the 11th tissue
sample (test data set), the probability to belong to the class “invasive breast
carcinoma,” “fibroadenoma,” or “healthy tissue” was predicted using the previously trained
PCA/LDA classifier. The optimal number of principal components that resulted in the
minimum classification error is selected in each iteration loop.
Results and Discussions
Figure 4A shows typical mean raw
spectra acquired from normal breast tissue, fibroadenoma, and invasive breast carcinoma
using 785 nm as excitation wavelength. Although one clearly can see the Raman peaks in the
raw mean spectrum acquired from the normal tissue, the Raman signatures are not visible in
the raw mean spectra acquired from the fibroadenoma or the invasive carcinoma. The spectra
of fibroadenoma and invasive carcinoma are dominated by the extremely strong
autofluorescence and look very similar. Therefore, a differentiation between normal breast
tissue and tumor breast tissue, irrespective of whether it is fibroadenoma or invasive
carcinoma, can be based solely on the very different appearance of their raw spectra.[13,14] For the differentiation between the 2 different tumor tissues, fibroademona and
invasive carcinoma, the pure Raman spectrum, which contains the desired and valuable
information about the chemical composition of the tissue, has to be refined from the
interfering fluorescence background. We here follow the SERDS approach as described and
motivated earlier.
Figure 4.
A, Mean raw spectra acquired from the 3 different breast tissue sites, normal (broken
black line), fibroadenoma (solid black line), and invasive breast carcinoma (solid gray
line) using 785 nm excitation wavelength. B, Reconstructed mean Raman spectrum of
fibroadenoma (dashed black line), invasive carcinoma (dotted black line), and normal
tissue (solid black line) together with standard deviation (shaded gray area).
A, Mean raw spectra acquired from the 3 different breast tissue sites, normal (broken
black line), fibroadenoma (solid black line), and invasive breast carcinoma (solid gray
line) using 785 nm excitation wavelength. B, Reconstructed mean Raman spectrum of
fibroadenoma (dashed black line), invasive carcinoma (dotted black line), and normal
tissue (solid black line) together with standard deviation (shaded gray area).Figure 4B shows as lines the mean
SERDS reconstructed Raman spectra of fibroadenoma, invasive breast carcinoma, and normal
tissue that were averaged from the 240 measurements made per tissue type. The gray
background shows the standard deviation of the 240 measurements. Due to the relatively small
fluorescence interference in the raw mean spectra of normal tissue, also the standard
deviation of the reconstructed Raman spectra of the normal tissue is relatively small.Figure 5A compares the mean
reconstructed Raman spectra of normal tissue (blue line), invasive breast carcinoma (red
line), and fibroadenoma (black line) and assigns to the Raman signatures of their molecular origin.[11,17,21,22,44,45] Additionally, the Raman spectrum of the fixation liquid formalin is provided as gray
line. Figure 5B shows in the form of
a difference spectrum where the main differences between the Raman spectra of fibroadenoma
and an invasive breast carcinoma can be found. Table 1 in detail assigns the Raman signatures to the
respective molecular vibrations.
Figure 5.
A, Mean reconstructed Raman spectrum of normal tissue (blue line), invasive carcinoma
(red line), fibroadenoma (black line), and formalin (thin gray line) with peak position
assignment to their respective molecular origin. B, Difference spectrum when the mean
Raman spectrum of fibroadenoma is subtracted from the mean Raman spectrum of invasive
breast carcinoma.
Table 1.
Assignment of Spectral Features in the Raman Spectrum to the Molecular Vibrations and
Molecular Origin.[11,17,21,22,44,45]
Normal
Invasive Carcinoma
Fibroadenoma
Major Assignments
Molecular Origin
1004 cm−1
1004 cm−1
Phenylalanine
Protein
1035 cm−1
1035 cm−1
C-H in plane bending mode of phenylalanine
Protein
1078 cm−1
C-C or C-O stretch
Lipid
1120 cm−1
V(C-C) of lipids from trans-segments
Lipid
1126 cm−1
1126 cm−1
C-N, C-C stretching
Protein
1210 cm−1
1210 cm−1
Tryptophan and phenylalanine V mode
Protein
1245 cm−1
1245 cm−1
Amide III, disorder structures of proteins, collagen
Protein
1268 cm−1
Amide III
Protein
1301 cm−1
1301 cm−1
CH2 twisting
Lipid
1340 cm−1
1340 cm−1
Adenine
Nucleic acid
1376 cm−1
CH3 symmetric deformation
Protein
1442 cm−1
CH2 deformation
Lipid
1451 cm−1
1454 cm−1
CH3 and CH2 deformation
Protein
1554 cm−1
1554 cm−1
Tryptophan
Protein
1586 cm−1
1586 cm−1
Phenylalanine
Protein
1657 cm−1
C=C band
Lipid
1660 cm−1
1660 cm−1
Amide I
Protein
1743 cm−1
V(C=O) lipids, esteryl, carbonyl, phospholipids
Lipid
A, Mean reconstructed Raman spectrum of normal tissue (blue line), invasive carcinoma
(red line), fibroadenoma (black line), and formalin (thin gray line) with peak position
assignment to their respective molecular origin. B, Difference spectrum when the mean
Raman spectrum of fibroadenoma is subtracted from the mean Raman spectrum of invasive
breast carcinoma.Assignment of Spectral Features in the Raman Spectrum to the Molecular Vibrations and
Molecular Origin.[11,17,21,22,44,45]The majority of the Raman bands/peaks of the normal tissue originate from lipids, as normal
breast tissue is mainly composed of fat with only small contributions from collagen.[14] On the contrary, the majority of the spectral features of tumor tissue originates
from proteins.[14]The normal tissue features strong lipid bands at 1078, 1120, 1301, 1442, 1657, and 1743
cm−1 assignable to C-C or C-O stretch vibrations, C-C vibration from
trans-segments, CH2 twisting vibrations, CH2 deformation vibrations,
C=C bend, and C=O vibrations of lipids. Weak protein bands at 1268 and 1374 cm−1
are visible due to amide III of proteins and CH3 deformation vibrations of
protein, respectively. Tumor tissue, irrespective of whether it is a fibroadenoma or an
invasive carcinoma, shows more protein Raman signatures. The characteristics peaks at 1004,
1245, 1340, 1451, and 1660 cm−1 are due to phenylalanine, amide I, nucleic acid,
the CH2 bend, and amide III, respectively. The phenylalanine Raman peak due to
the C-H in plane bending mode appears at around 1035 cm−1.[22,44] In our case, it appears shifted to around 1039 cm−1 probably due to the
minimal interference with the largest Raman peak of formalin at around 1041
cm−1.Considering the reconstructed Raman spectra shown in Figure 5A, several clear spectral features
differentiate between normal breast tissue and tumor tissue, irrespective of whether the
tumor is fibroadenoma or an invasive breast carcinoma. In normal breast tissue, the C=C band
of lipids at 1657 cm−1 is sharper than the amide I band (1660 cm−1) of
protein in the tumor tissue. The shift between the CH2 band of lipids and
proteins around 1442 and 1451 cm−1 can also be considered as a criterion for
differentiation. In contrast to the amide III band of normal breast tissue at 1268
cm−1, the tumor tissues feature a broader amide III band at 1245
cm−1. The absence of the phenylalanine (1004 cm−1) and the nucleic
acid (1340 cm−1) Raman bands in the Raman spectrum of normal tissue is another
criterion for classification. Moreover, the intensity of the entire Raman spectrum in the
shown spectral range can be considered to differentiate between normal and tumor breast
tissue.However, the differences between the 2 tumor tissues, fibroadenoma and the invasive
carcinoma, are significantly less pronounced but are made visible in the difference spectrum
in Figure 5B. The negative peaks at
1004, ∼1035, 1210, 1245, 1554, and 1660 cm−1 indicate the presence of relatively
more proteins in fibroadenoma than in invasive carcinoma.[15,17] Furthermore, the positive peaks indicate the presence of relatively more lipids in
the invasive carcinoma than in fibroadenoma. As reported by Chowdary et al,[17] this could be due to the more stromal component in fibroadenoma tissue relative to
more cellular components of invasive carcinoma tissue.Considering the reconstructed Raman spectra shown in Figure 5A again, criteria for the differentiation
between fibroadenoma and invasive carcinoma could be for example (1) the small shift of the
CH3 and CH2 deformation band of protein from 1451 to 1454
cm−1 (2) or at 1301 cm−1, the lipid peak of the invasive breast
carcinoma, which we did not see in the spectra of fibroadenoma.We followed a PCA method to objectively differentiate between the different tissue types.
Figure 6 shows the PCA of the 240
measurements per tissue type for the principal components 1 and 2 in a plane. The scattering
of the data points, which are rectangles for normal breast tissue, circles for fibroadenoma,
and triangles for invasive carcinoma visualizes the possibility of differentiating between
them and the reproducibility from one measurement to another. The high concentration of
rectangles in a rather small region indicates that the 240 reconstructed Raman spectra of
normal breast tissue are reproducible, irrespective of measurement location on 1 tissue
sample and even irrespective of the patient the tissue type came from. The clear separation
of the rectangles from the triangles and from the circles indicates that the 240
reconstructed Raman spectra of normal breast tissue can clearly be separated from tumor
tissue. The first principal component accounts for 72.67% of the total variance in the
reconstructed Raman spectra.
Figure 6.
Principal component analysis scores of Raman spectra of invasive breast carcinoma,
fibroadenoma, and health breast tissue collected from 11 human female patients.
Principal component analysis scores of Raman spectra of invasive breast carcinoma,
fibroadenoma, and health breast tissue collected from 11 human female patients.Figure 7 illustrates the loading
plot for the first 4 principal components as a function of the Raman shift. The main
contributions to the first principal component are the C-C or C-O stretch- (1078
cm−1), the CH2 twisting- (1301 cm−1), the CH2
deformation- (1442 cm−1), and the C=C band vibration of lipids (1657
cm−1) and amide III (1268 cm−1).
Figure 7.
Loading plot for the first 4 principal components as a function of Raman shift.
Loading plot for the first 4 principal components as a function of Raman shift.The second principal component contains 7.74% of the spectral variation related to the
vibrations of phenylalanine (1004 cm−1), the C-N or C-C stretching vibration of
proteins (1126 cm−1), the amide III - (1245 cm−1), amide I - (1660
cm−1), and nucleic acid vibration (1340 cm−1). The third principal
component comprises 6.92% of the data variance assignable mainly to vibrations of
phenylalanine (1004 cm−1) and the CH3 and CH2 deformation
vibration of proteins (1454 cm−1). The fourth principal component accounts to
2.61% of the data variance mainly assignable to amide III (1268 cm−1). The
variance content of the principal components demonstrates that the differentiation between
the breast tissues types is sensitive to the composition of the tissue. Figure 6 shows that based on the PCA also fibroadenoma
can be differentiated efficiently from an invasive breast carcinoma. There is only a little
overlap between the region comprising the triangles and the region comprising the circles.
The large scatter of the 240 triangles and the 240 circles is due to (1) the worse quality
of the reconstructed Raman spectra obtainable from tumor tissue (compare Figure 4B) and (2) due to the higher
variation in the biochemical composition of tumor tissue. Nevertheless, the general
differentiability between the 3 different tissue types with PCA confirms that the standard
deviation from one measurement point to another measurement point, from sample to sample and
from patient to patient, is small compared to the differences originating from a variation
in the molecular composition.Figure 8 illustrates the
receiver–operating characteristic curve that explains the performance of the classifier. The
normal tissue can be differentiated from the tumor tissues with zero classification error.
Additionally, our results indicate a high sensitivity (true positive rate) of 99.15% for
invasive breast carcinoma and a high specificity (true negative rate) of 90.40% for
fibroadenoma.
Figure 8.
Receiver–operating characteristic (ROC) curve explaining the performance of the
principal component analysis (PCA)/ linear discriminant analysis (LDA) classifier,
between normal and tumor tissue (blue curve, sensitivity of 100%, specificity of 100,
and area under the curve [AUC] of 1), and between invasive breast carcinoma and
fibroadenoma (black curve, sensitivity of 99.15%, specificity of 90.40%, and AUC =
0.9455).
Receiver–operating characteristic (ROC) curve explaining the performance of the
principal component analysis (PCA)/ linear discriminant analysis (LDA) classifier,
between normal and tumor tissue (blue curve, sensitivity of 100%, specificity of 100,
and area under the curve [AUC] of 1), and between invasive breast carcinoma and
fibroadenoma (black curve, sensitivity of 99.15%, specificity of 90.40%, and AUC =
0.9455).Several pathology studies[4,15,17,44,45] show the predominance of lipids in normal tissues and proteins in tumor tissues. The
Raman bands/peaks shown in our results in relation with their molecular origin presented in
Table 1 confirm this
relationship. In the study by Frank et al, breast cancer samples stored in
a solution of 10% formalin with 50 mmol/L phosphate buffer (pH 6-7) were analyzed using
Near-IR Raman spectroscopy. Frank et al
[45] noted significant and reproducible differences between normal and tumor tissues
mainly contributed due to the shift of the Raman band/peak at around 1442 cm−1 in
normal tissue to around 1451 cm−1 in tumor tissues. They also reported the
differences between benign and malign lesions were less obvious. Concerning the differences
between the tumor tissues, our results correlate well with the studies of Chowdary
et al
[17] and Haka et al.[15] Chowdary et al
[17] applied Raman spectroscopy to diagnose breast tissue specimens, from routine surgical
resections, procured in ice-cold saline and reported very good classification of normal,
benign, and malign tissues. Applying spectral deconvolution, they found the dominance of
lipid bands (1301 and 1442 cm−1) in normal tissue and lowest contribution of
these spectral features in fibroadenoma. Besides, they showed strong presence of protein
bands (1246, 1455, and 1656 cm−1) in fibroadenoma than in invasive carcinoma
which reflects our findings in Figure
5B. Similarly, Haka et al
[15] confirmed the dominance of protein bands in fibroadenoma as compared to invasive
carcinoma by analyzing breast tissue samples snap-frozen in liquid nitrogen. By applying a
diagnostic model based on fit coefficients for collagen and fat, they showed the percentage
of collagen is higher in fibroadenoma while the percentage of fat is maximal in normal
tissue.
Conclusion
Our results show that invasive breast carcinoma can be differentiated from fibroadenoma
with a high accuracy by isolating the “pure” Raman spectrum of the respective tissue from
its heavily fluorescence interfered raw spectrum following the SERDS method. Still this
method relies on the prior resection of the tissue from the patient but in principle enables
fast and objective screening of the resected tissue directly in the surgery hall without any
kind of sample preparation. Of course, it will not substitute the detailed histopathological
analysis, which will provide the final decision on the classification of the resected
tissue, but in the intraoperative surgical setting, it can provide a first indication to the
surgeon whether or not the resection margins of the surgical specimen are carcinoma
free.
Authors: Kristina Noack; Björn Eskofier; Johannes Kiefer; Christina Dilk; Georg Bilow; Matthias Schirmer; Rainer Buchholz; Alfred Leipertz Journal: Analyst Date: 2013-10-07 Impact factor: 4.616
Authors: C-H Liu; Y Zhou; Y Sun; J Y Li; L X Zhou; S Boydston-White; V Masilamani; K Zhu; Y Pu; R R Alfano Journal: Technol Cancer Res Treat Date: 2013-02-22
Authors: Florian Korinth; Elmar Schmälzlin; Clara Stiebing; Tanya Urrutia; Genoveva Micheva; Christer Sandin; André Müller; Martin Maiwald; Bernd Sumpf; Christoph Krafft; Günther Tränkle; Martin M Roth; Jürgen Popp Journal: Sensors (Basel) Date: 2020-11-24 Impact factor: 3.576